Overview

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Status:
NOT_YET_RECRUITING

Trial end date:
2031-04-15

Target enrollment:

Participant gender:

Summary

This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

Phase:

PHASE1

Details

Lead Sponsor:

City of Hope Medical Center

Collaborator:

Jaeb Center for Health Research

Treatments:

Adalimumab
Antilymphocyte Serum
thymoglobulin